Industry News
Biotron adds dengue virus to discovery roster
Canberra biotechnology company Biotron (ASX: BIT) has added dengue virus to the lengthening list of potentially lethal human viruses that possess ion-channel genes. [ + ]
UK hints at end to drug price controls
The British government said it might be possible to relax or abolish price and profit controls on branded prescription medicines in the UK. [ + ]
Agenix appoints new US vet distributor
Brisbane-based Agenix (ASX:AGX) has appointed a new distributor for its animal health diagnostic products in the US. [ + ]
Arthritis CRC picks up new funding and partners
The Cooperative Research Centre for Chronic Inflammatory Diseases has received AUD$5 million in supplementary funding from the federal government to implement two new programs. [ + ]
Compumedics revenues, losses up
Compumedics' (ASX:CMP) revenues for the 2002-2003 financial year were up 62 per cent to AUD$32 million, reflecting strong growth in the company's sleep diagnostics business. [ + ]
Anadis therapy aiming to ease travellers' paths
It's a malady with many colourful names -- Montezuma's revenge, Delhi belly, the Karachi Crouch -- but traveller's diarrhoea, by any other name, has disembowelled many a costly overseas holiday or business trip. [ + ]
Patent could lead to new royalty revenue: CSL
A new US patent issued to CSL (ASX:CSL) and the University of Queensland over human papillomavirus (HPV) will lead to royalty revenue if drug giant Merck launches a vaccine for the virus in the US. [ + ]
Do you have hyperactive platelets?
A researcher at the University of Newcastle is looking for patients with type-2 diabetes who are currently not taking anti-platelet medication for a new study involving tomato juice and fish oil!
[ + ]PanBio tips profit for 2003-04
Queensland-based diagnostics company PanBio (ASX:PBO) has ended the financial year with an anticipated loss, but expects the 2003-2004 year to be profitable, said chairman Ian Sandford today. [ + ]
AustCancer finds cancer jammer molecule
Perth-based cancer therapeutics developer Australian Cancer Technology's (ASX:ACU) joint discovery project with Cambridge-based BioFocus (AIM:BIO) has designed a tiny spanner to jam the molecular works of cancer cells that evade conventional chemotherapy and radiotherapy. [ + ]
Hunt for SARS source far from over: researcher
Virologists have some suspects, but the animal that originally hosted the lethal coronavirus that causes severe acute respiratory syndrome (SARS) in humans remains unidentified. [ + ]
New online publishing system boosts access to resources
In a boost for Australasian research, leading e-publisher RMIT Publishing has announced the release of a new online publishing and content management system to provide researchers with better access to a wide range of Australasian online resources currently available on its Informit Online service.
[ + ]S&P raises ResMed ratings
Standard & Poor's ratings services has raised its corporate credit rating on ResMed (ASX:RMD) to 'BB-' from 'B+', and raised its senior subordinated debt rating on the company to 'B' from 'B-'. [ + ]
Qld's Élan joins with US Meditech on biohazard
Queensland company Élan BioDynamics, a wholly owned subsidiary of the Élan Group, has entered a joint venture with US company Meditech Pharmaceuticals to commercialise a system for detection of biological hazards including aflatoxin, and anthrax. [ + ]
Pest solution goes back for mouse-to-mouse resuscitation
Plans to conduct the first contained field trial of a transgenic virus designed to prevent episodic plagues of the house mouse in the Australian wheat belt have been set back while researchers work to improve its transmission under field conditions [ + ]
